IPSEN (OTCMKTS:IPSEY) Stock Price Down 6.2% – Here’s Why

IPSEN (OTCMKTS:IPSEY) shares fell 6.2% on Tuesday . The stock traded as low as $44.74 and last traded at $44.74. Approximately 256 shares traded hands during trading, a decline of 88% from the average daily volume of 2,197 shares. The stock had previously closed at $47.72.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

IPSEN Stock Performance

The stock’s 50 day simple moving average is $47.03 and its two-hundred day simple moving average is $44.62.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).